Buy Methallylescaline (MAL) Cas 207740-41-8
Buy Methallylescaline (MAL) Cas 207740-41-8
Methallylescaline (MAL), also known as 4-methylallyloxy-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][3] It is taken orally.[1][3]
The drug acts as a serotonin 5-HT2 receptor agonist, including of the serotonin 5-HT2A receptor.[4][5] It is closely structurally related to mescaline and to other scalines like escaline and allylescaline.[5]
Methallylescaline was first described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[3][1] It was encountered as a novel designer drug by 2013.[6][7][8]
Use and effects
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists the dose range of methallylescaline as 40 to 65 mg and its duration as 12 to 16 hours.[1][9][10] As such, its dose range is relatively narrow.[1][9][10] Moreover, the drug has been reported to have an unusually steep dose–response curve, such that a small increase in dose can result in an unexpectedly large increase in effects.[11][12] Methallylescaline has about 6 times the potency of mescaline, which has a much higher listed dose range of 200 to 400 mg.[9][10][1] Its onset is within 1 hour and peak effects occur within 2 hours.[1]
Shulgin has described methallylescaline as a “mixed bag” in terms of experience reports.[1] Its effects have been reported to include closed-eye visuals, “visual theater”, open-eye visuals including visual distortions, visual depth and movement effects, kaleidoscopic neon colors, watercolors, fantasy, mental imagery, feelings of unreality, easy childhood memory recall, self-connectedness, eroticism, initial discomfort, overload, feeling overwhelmed, shades of possible amnesia, loss of contact, extreme restlessness, trouble sleeping, and enhanced dreams.[1] It was also reported to produce quite strong body effects, diuretic effects, and slightly reduced heart rate.[1] Some found it unpleasant and said that they would not repeat the experience, whereas others were impressed by it, found it enjoyable, and called it “beautiful”.[1] Many expressed that the dose they tried was too strong for them and that a lower dose would be better.[1] Methallylescaline has been described as having relatively more visual imagery than other scalines like cyclopropylmescaline and allylescaline.[1]
Others have noted that methallylescaline has strong visual effects, as well as prominent nausea, vomiting, and body load, including feeling “overstimulated.[11] The drug is frequently compared to mescaline.[11]
Interactions
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 5,100–>10,000 |
| 5-HT1B | >10,000 |
| 5-HT1D | 2,754 |
| 5-HT1E | >10,000 |
| 5-HT1F | ND |
| 5-HT2A | 72–955 (Ki) 8.5–891 (EC50Tooltip half-maximal effective concentration) 19–110% (EmaxTooltip maximal efficacy) |
| 5-HT2B | 110 (Ki) 4.9–>10,000 (EC50) 32–103% (Emax) |
| 5-HT2C | 5.1–520 (Ki) 1.8–331 (EC50) 75–102% (Emax) |
| 5-HT3 | >10,000 |
| 5-HT4 | ND |
| 5-HT5A | >10,000 |
| 5-HT6 | >10,000 |
| 5-HT7 | >10,000 |
| α1A–α1D | >10,000 |
| α2A | 550–1,500 |
| α2B, α2C | >10,000 |
| β1–β3 | >10,000 |
| D1–D5 | >10,000 |
| H1–H4 | >10,000 |
| M1–M5 | >10,000 |
| TAAR1 | 1,000 (Ki) (rat) 3,900 (Ki) (mouse) (EC50) (rodent) >10,000 (EC50) (human) |
| I1 | ND |
| σ1 | >10,000 |
| σ2 | 5,248 |
| SERTTooltip Serotonin transporter | >10,000 (Ki) ND (IC50Tooltip half-maximal inhibitory concentration) |
| NETTooltip Norepinephrine transporter | >10,000 (Ki) ND (IC50) |
| DATTooltip Dopamine transporter | >10,000 (Ki) ND (IC50) |
| Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [4][5][13][14] | |
Methallylescaline acts as a potent agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, among other actions.[4][5][13][14] It was inactive serotonin 5-HT2B receptor agonist in one study,[5] but was a potent agonist in another study.[4] The comprehensive receptor interactions of methallylescaline have been studied.[4]
The drug produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents.[14] Surprisingly, the HTR induced by methallylescaline was blocked by the selective serotonin 5-HT2C receptor antagonist SB-242084 but not by the serotonin 5-HT2A receptor antagonist ketanserin.[14]
In addition to its psychedelic-like effects, methallylescaline produces hyperlocomotion (a stimulant-like effect), conditioned place preference (CPP; a rewarding effect), and modest self-administration (a reinforcing effect) in rodents, among other effects.[15]
Methallylescaline, along with BOD and DOI, has been reported to produce serotonergic neurotoxicity in rodents at high doses given repeatedly.[14] Other psychedelics have also been found to produce neurotoxicity in preclinical research.[16][17][18]
Pharmacokinetics
The metabolism of methallylescaline has been studied.[19][20]
Chemistry
Methallylescaline, also known as 4-methylallyloxy-3,5-dimethoxyphenethylamine, is a substituted phenethylamine and scaline.[1][3][9][10] It is a synthetic derivative of mescaline (3,4,5-trimethoxyphenethylamine) with a methallyloxy group instead of methoxy group at the 4 position.[1][3][9][10]
Synthesis
The chemical synthesis of methallylescaline has been described.[1]
Analogues
Analogues of methallylescaline include mescaline, escaline, allylescaline, propynyl, and cyclopropylmescaline, among others.[1][3][9][10][21] Some other analogues include 3C-MAL, 2C-T-3, 2C-O-3, and MMALM.[1][3][21]
History
Methallylescaline was first described in the literature by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[3][1][9] It was first tried by Shulgin in 1981 and its hallucinogenic effects were discovered by him in 1982.[22][10] The drug has an entry in PiHKAL, but not in Shulgin’s 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds.[3] It was encountered as a novel designer drug in Europe by 2013.[6][7][8] Methallylescaline’s pharmacology was described by Matthias Liechti and Daniel Trachsel and colleagues in 2021.[5] Discussion of methallylescaline online began increasing in late 2023.[11]
Society and culture
Names
Alexander Shulgin described the name of methallylescaline (MAL) as “completely unsound”.[1] This was because there was no union of a methallyl group with escaline.[1] Instead, methallylescaline is mescaline with a 2-propene group attached to the methyl of the methoxy group at the 4 position.[1] However, Shulgin expressed that there is no way of naming the compound in that manner.[1] The only corresponding proper name would be 4-methylallyldesmethylmescaline (MAD).[1] However, Shulgin found the acronym MAD to be disagreeable and ultimately preferred MAL.[1]
Legal status
Canada
Methallylescaline is not a controlled substance in Canada as of 2025.[23]
Sweden
Methallylescaline is illegal in Sweden as of 26 January 2016.[24]
United States
Methallylescaline is not explicitly scheduled under the Controlled Substances Act.[25] However, due to its structural similarities with mescaline, it could potentially be prosecuted under the Federal Analogue Act if sold for human consumption.
Reviews
There are no reviews yet.